NEULANDLAB · Healthcare
Not filed yet. The deadline is 30 May 2025.
| Q2 FY26 | Q1 FY27 | Q2 FY27 | |
|---|---|---|---|
| Revenue | ₹514 cr | ₹642 cr | ₹450 cr |
| YoY | — | — | −13% |
| EBITDA margin | 30.2% | 34.7% | 21.6% |
| Other income, % of PBT | 1% | 4% | 11% |
| Exceptional items | — | — | — |
| Tax rate | 25% | 25% | 25% |
| Net profit | ₹96.5 cr | ₹147 cr | ₹51.1 cr |
| YoY | — | — | −47% |
| Core profit YoY | — | — | −52% |
| EPS | ₹75.18 | ₹114.86 | ₹39.85 |
| Flags | · | · | 1 |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.